The replication-incompetent HSV-1-based vectors are herpesviruses in which genes that are 'essential' for viral replication have been either mutated or deleted. These deletions have substantially reduced their cytotoxicity by preventing early and late viral gene expression and, together with other deletions involving 'nonessential' genes, have also created space to introduce distinct and independently regulated expression cassettes for different transgenes. Therapeutic effects in gene therapy applications requiring simultaneous and synergic expression of multiple gene products are easily achievable with these vectors. A number of different HSV-1-based nonreplicative vectors for specific gene therapy applications have been developed so far. They have been tested in different gene therapy animal models of neuropathies (Parkinson's disease, chronic pain, spinal cord injury pain) and lysosomal storage disorders. Many replicationincompetent HSV-1-based vectors have also been used either as potential anti-herpes vaccines, as well as vaccine vectors for other pathogens in murine and simian models. Anticancer gene therapy approaches have also been successfully set up; gene therapy to other targets by using these vectors is feasible. Gene Therapy (2005) 12, S98-S102.
Introduction
Many diseases are the consequence of single or multifactorial gene defects. A greater understanding of the molecular, biochemical and genetic factors that entail the progression of a specific disease state has led to the development of gene therapy-based strategies using direct gene transfer either to ameliorate the disease condition or to correct a genetic defect. Several gene delivery approaches have been explored, each of which has both advantages and disadvantages but natural gene transfer agents such as viruses remain by far the most efficient and proven vectors.
Recombinant nonreplicative Herpes simplex viruses (HSV) are potential vectors for several applications in human health (Figure 1 ). These include: (i) delivery and expression of human genes to central nervous system (CNS) cells, (ii) selective destruction of cancer cells, (iii) prophylaxis and immunotherapy against tumors and (iv) prophylaxis against HSV-mediated and other infectious diseases. Each application requires a different kind of vector and, in principle, different kinds of genetic engineering. Some gene therapy applications will require short-term transgene expression, while others will demand a long-term expression of the exogenous gene. Although delivery of a single gene should be adequate in many cases, other applications will likely require the delivery of multiple transgenes. One of the major advantages of nonreplicative vectors is the possibility, due to their capacity to accommodate multiple transgenes in one vector, to achieve a synergistic therapeutic effect in gene therapy applications of multifactorial diseases.
The replication-defective HSVs are viral vectors, where 'essential' genes for in vitro viral replication are either mutated or deleted. Immediate-early (IE) genes, which encode infected cell proteins (ICP) ICP0, ICP4, ICP22, ICP27 and ICP47, are expressed shortly after viral entry into the host cell and are required for initiation of the cascade of early (E) and late (L) viral gene transcription. ICP4 and ICP27 are essential for replication and the deletion of one or both of them requires adequate complementing cell lines capable of providing in trans the deleted viral proteins. 1, 2 Besides its transcriptional functions, ICP27 also affects the splicing, polyadenylation and stability of mRNAs and inhibits the transcription of many host genes. [3] [4] [5] ICP0 is a multifunctional protein acting as a promiscuous transactivator, able to modify host functions in order to promote viral gene expression and viral productive infection. 6, 7 ICP22 is a nonessential regulatory protein required for optimal expression of the ICP0 protein; deletion of the ICP22 IE gene can be responsible for a disregulated expression of ICP0. ICP47 inhibits MHC class I antigen presentation contributing to the virus escape from the immune surveillance. 8 The 'first generation' of replication-defective HSV-1-based vectors consisted of mutants deleted in the single essential IE gene encoding ICP4, namely d120 and S4TK vectors. 9, 10 Although these vectors show reduced pathogenicity and can be used to efficiently transfer and transiently express reporter genes in brain, they are nonetheless cytotoxic for neurons in culture. It is presumed that residual cytotoxicity results from the expression of the other four IE genes. ICP4, ICP27, ICP0 and ICP22 have all been shown to be toxic in stable transfection assays, 2 so deletion of these genes in combination is required to eliminate toxicity. 9, [11] [12] [13] [14] Cell lines that complement ICP4 and ICP27 have permitted the construction of a 'second generation' of highly defective mutants. [14] [15] [16] These multiple-deleted mutants show substantially reduced cytotoxicity for neurons in culture and unusually prolonged transgene expression from the ICP0 IE promoter or the HCMV IE promoter in neurons in vitro. To date, several replication-defective vectors have been constructed in which ICP0, ICP4, ICP27, ICP22 and ICP47 genes have been deleted in various combinations. 12, 17 The second generation of replication-defective vectors are characterized by absence of early and late viral gene expression and provide enough space to introduce distinct and independently regulated expression cassettes for different transgenes. 12 Deletion of all the five IE genes (ICP0, ICP4, ICP22, ICP27 and ICP47) prevents virus toxicity for cells at high multiplicity of infection, allowing the vector genome to persist in cells for long periods of time. 18 However, these vectors grow poorly in culture and express transgenes at very low levels in the absence of ICP0 transactivator. 17 
Construction of nonreplicative HSV-1-based vectors: engineering techniques
Modifications of the HSV genome can be achieved in a number of ways. They usually require a two-step process in which portions of the herpes genome, that have been cloned into plasmid vectors, are first modified in vitro. The plasmid DNA is then cotransfected into cultured cells with infectious wild-type viral DNA and recombinant viruses are selected. Several methods have been described to insert exogenous DNA sequences into the viral genome. Technique designs to enhance the frequency of recombination has been described. Efficient insertion of transgenes into specific sites within the viral genome has been achieved in vitro using a recombination system derived from phage P1. 19 Among various strategies for targeted deletion of genes within a specific viral locus, a rapid two-step method has been successfully used to facilitate the insertion of foreign sequences into the viral genome. The first step requires the insertion of a reporter gene cassette (Escherichia coli b-galactosidase, lacZ) flanked either by PacI or PmeI restriction recognition sites that are absent in the viral genome and surrounded by HSV sequences necessary for homologous recombination with the viral genome. 10, 20 The recombinant viral progeny is then selected by a 'blue plaque' phenotype after X-gal staining. The second step consists in the removal of the lacZ reporter gene from the recombinant virus, now containing the PacI sites, that results in the generation of two large fragments unable to produce infectious viral particles. The PacI-deleted fragment is then replaced by the heterologous gene, following cotransfection of the complementing cell line with the deleted HSV-1 viral genome and the plasmid containing the transgene. Potential recombinants are identified by the 'clear plaque' phenotype after X-gal staining. The insertion of the transgene construct into the viral genome eliminates the PacI sites, and allows the use of this method repeatedly to insert multiple transgenes in different loci of HSV-1 genome. This methodology increases the frequency (ranging from 40 to 90%, instead of from 4 to 5%) of the homologous recombination between the viral genome and the HSV sequences present in the plasmid.
A different procedure involves transfection of cells with overlapping cosmids containing appropriate insertion or deletions. Expression of genes contained in cosmids leads through recombination to the construction of full-length viral genome. 21 To select recombinant vectors it is critical to have a system by which to identify successful recombinants containing the deletions and the transgenes.
Viral stocks production and purification
The large-scale HSV-1 recombinant vectors production is currently performed by purifying the viral particles from cell debris by low-speed centrifugation followed by highspeed centrifugation on density gradient. 22, 23 This practice is, however, both time-and labor-consuming and is thus not suitable for the manufacturing processes at the industrial scale. Efforts have been made recently to substitute the density gradient purification method with a more efficient and cheaper purification practice represented by column chromatography. Successful use of immobilized metal affinity chromatography (IMAC) in the viral particles purification has been reported in a recent publication. 24 Furthermore, optimal culture conditions to facilitate large-scale preparation of nonreplicative vector stocks have also been described. 25 Gene transfer in the nervous system HSV has evolved to persist in neurons as an episomal element in a potentially life-long latent state and without interference with host cell function; these characteristics Figure 1 Schematic representation of a second generation replicationincompetent HSV-1-based gene transfer vector prototype, and its potential fields of application. These vectors have been obtained by deletion of ICP27, ICP4 (both copies) and ICP22 IE genes, as indicated by red boxes; yellow boxes represent loci that can be deleted and substituted by exogenous DNA sequences, to obtain vectors expressing multiple gene products simultaneously.
Replication-incompetent HSV-1-based vectors E Berto et al make replication-defective viruses an attractive vehicle for gene therapy of neural tissue. 26 However, the genetic modifications of these viruses introduced to reduce their pathogenicity and increase their safety profile often result also in the loss of viral activities required for efficient gene delivery and life-long persistence within the host. As for the long-term transgene expression, it is still controversial which promoter would better suit this purpose in vivo. Based on previous studies, it seems likely that the latency-associated transcript (LAT) promoters, namely latency-active promoters LAP1 and LAP2, may be the most effective in the long-term expression of transgenes in neurons. 27, 28 Hybrid variants of these promoters constituted by LAP elements linked to strong viral IE promoters and able to sustain longterm expression of a transgene have been reported. 29, 30 Nonreplicative HSV vectors have been tested in many different gene therapy animal models of various neuropathies (Parkinson's disease, 31 ,32 chronic pain, 33 spinal cord injury pain, 34 cisplatin neuropathy 35 ) or lysosomal storage disorders with neurological involvement (manuscript in preparation). Among them, vectors expressing multiple trophic factors seem to be very promising as a side treatment for neurodegenerative diseases. Motor neuron disease (MND) is a group of neurological diseases characterized by the degenerative process of the upper and lower motor neurons 36 in different parts of the motor system including the spinal cord, brain stem and motor cortex. Experimental evidence indicates that treatment with multiple neurotrophic factors can significantly increase motor neuron survival in comparison with the delivery of a single factor alone. 15, 37 HSV vectors have been engineered to express multiple neurotrophic factors and used to deliver these molecules to specific motor neuron populations. Nonreplicative vectors containing bFGF, CNTF and EGFP (as a reporter gene) have already been shown to induce proliferation and differentiation in O-2A oligospheres obtained from newborn rat brains in vitro and also in the rat hippocampus in vivo (Figure 2 ). 38 Therapy of lysosomal storage disorders with neurological involvement such as Tay-Sachs (TS) disease requires production and distribution of the missing enzyme into the CNS. Several therapeutic approaches allow restoring the defective enzymatic activity in many key tissues (kidney, liver, spleen, etc) but the reduction of the GM2 ganglioside deposits in the CNS is difficult to achieve since CNS is kept in a privileged environment, separated from the blood system by the blood-brain barrier (BBB), representing an obstacle to therapy. S Martino and co-workers (manuscript in preparation) have demonstrated that a nonreplicating Herpes simplex vector encoding the hexosaminidase (Hex) A a-subunit (HSV-T0aHex) when delivered into the internal capsule of the TS brain animal model was able to reestablish the Hex A activity resulting in the removal of the GM2 ganglioside storage in both injected and controlateral hemisphere and in the cerebellum 1 month after treatment.
Vaccination
The use of HSV vectors for prophylaxis against viral infections and tumors requires genetically stable mutants, incapable of replicating in CNS and of spreading in immunocompromised individuals, unable to reactivate, not transmissible from immunized vaccinated individuals to contacts; however, the recombinant viral vectors have to retain their immunogenicity in order to elicit protective immunity against diseases in their hosts. A large number of defective viruses have been proposed for immunization on the ground that although they cannot produce infectious progeny and fundamentally make proteins only in the set of initially infected cells, the presentation of viral antigens and/or transgene, synthesized ex novo in these cells, to the host's immune system is able to elicit long-lived and potent cellular and humoral immune responses. Various nonreplicative HSV-1-based vectors have been successfully used either as potential anti-herpes vaccines in murine model [39] [40] [41] or as vaccine vectors in murine and simian models. Murphy et al 42 have demonstrated that two of the seven rhesus monkeys vaccinated with recombinant HSV expressing HIV antigenes were solidly protected, and another showed a sustained reduction in viral load following rectal challenge with pathogenic SIVmac239. A previous study performed in mice by T Brocker and our group has shown the efficacy of recombinant HSV-1 vaccines by using a vector expressing chicken ovalbumin. 43 A single vaccination, with a strong antigen as ovalbumine, was sufficient to elicit a protective immune response characterized by high frequency of both primary and memory antigene-specific CTL response. Poor induction of CD4 helper T-cell responses and a similarly weak induction of T-dependent antibodies were observed. Apparently, the lack of antibodies did not negatively affect the ability of HSV-1-derived vaccines to give longterm protection against L. monocytogenes expressing Ova. The results obtained with Ova viral vector are in accordance with the data we collected by immunizing mice with an HIV-1 Tat expressing nonreplicative vector (manuscript in preparation). Notably, herpes simplex viral recombinants have been reported to elicit antigenspecific immune response, despite pre-existing immu- 48 These mutant vectors express, in association with the autologous HSV-1 thymidine kinase (tk) gene acting as a suicide gene when accompanied by its prodrug ganciclovir (GCV), further transgenes chosen for their potential to synergize in tumor cell killing and induction of antitumor immunity. Among immunostimulatory molecules, soluble human cytokines Interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF), Interferon-g (IFN-g), human tumor necrosis factor-a (TNFa) 49 and also the costimulatory surface antigen CD80-encoding genes have been studied. 12 Furthermore, rat connexin 43 gene has been successfully used to improve the HSV-1 TK/GCV killing of glioma cells by increasing the TK/GCV proximal bystander effect. 50 Recently, an HSV-1-derived replication-defective vector (T0-IFI16) has been developed, which has been shown to efficiently transduce an interferon-inducible gene (IFI16), into primary human umbilical vein endothelial cells (HUVEC), which are usually poorly transfectable. 51 We have also been able to infect HUVEC cells with similar HSV-1-based vectors expressing antiangiogenic fusion proteins endostatin::angiostatin and endostatin::kringle 5. The expression of antiangiogenic proteins by directly infected HUVEC cells has been shown to induce cytostatic effects in proliferation assays in vitro. Also, by addition of ganciclovir to the cell culture media, we have obtained major cell killing effect too (manuscript in preparation).
New targets for future gene therapy applications
In a recent publication, a replication-defective HSV-1 vector has been used to deliver and express nerve growth factor (NGF) in a rat model of diabetic cystopathy. Encouraging results were obtained, thus suggesting a potential role of HSV vectors to restore decreased NGF expression in the bladder and bladderafferent pathways. 52 Moreover, Fradette et al 53 have developed a highly defective HSV-1 vector expressing glial cell-line-derived neurotrophic factor (GDNF) under the control of a chimeric LAP2-HCMV promoter, and have demonstrated a sustained transgene production in adipose cells in culture and in rabbit fat tissue. These experiments establish the efficient transduction of adipose cells by HSV vectors and suggest that fat tissue may represent a useful site for HSV-mediated gene delivery with potential for therapeutic applications.
Conclusions
A number of different HSV-1-based nonreplicative vectors for specific gene therapy applications have been developed so far. The challenge for scientists is to develop the means to render these vectors harmless yet effective for targeted gene transfer and appropriate gene expression. Recent advances and present applications of existing vectors, are focused on improving the characteristics of these vectors. Efforts are being made, in particular, to reduce their toxicity, to modulate the breadth and the time course of transgene expression, to precisely target specific cell populations and to transfer multiple genes by a unique vector. These recombinant viruses with reduced cytotoxicity can represent a very efficient delivery reagent for gene transfer in vitro and in vivo. Multiple exogenous genes delivery, whether they are synergistically acting or not, is easily achievable with these HSV mutants and thus suggests their possible clinical applications in multifactorial diseases such as tumors and neurodegenerative diseases.
